Abstract | BACKGROUND: METHODS: RESULTS:
Teriparatide therapy was initiated 32±14 days after the development of hypocalcemia. As a result, calcemia levels increased (median±standard deviation [SD]: 6.7±0.8 vs. 8.5±0.8 mg/dL, P=0.024) allowing suspension of intravenous calcium in two patients and reduction of calcitriol doses (mean±SD: 1.1±0.38 vs. 0.55±0.27 μg/day, P=0.004). In addition, phosphatemia levels (median±SD: 5.1±1.5 vs. 3.9±0.5 mg/dL, P=0.09) and calcium carbonate requirements (mean±SD: 13.8±9.4 vs. 7.2 ±3.7 g/day, P=0.9) exhibited declining trends. No secondary effects were observed and creatinemia remained stable. CONCLUSIONS:
|
Authors | Estela L Nogueira, Ana C Costa, Alice Santana, José O Guerra, Sónia Silva, Clara Mil-Homens, António G Costa |
Journal | Transplantation
(Transplantation)
Vol. 92
Issue 3
Pg. 316-20
(Aug 15 2011)
ISSN: 1534-6080 [Electronic] United States |
PMID | 21694663
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Bone Density Conservation Agents
- Teriparatide
|
Topics |
- Adult
- Bone Density Conservation Agents
(therapeutic use)
- Female
- Humans
- Hyperparathyroidism, Secondary
(drug therapy)
- Hypocalcemia
(drug therapy, etiology)
- Kidney Transplantation
- Male
- Middle Aged
- Parathyroidectomy
(adverse effects)
- Severity of Illness Index
- Teriparatide
(therapeutic use)
- Treatment Outcome
|